The neuropathobiology of multiple sclerosis.

Veröffentlicht: von & gespeichert unter Allgemein.

Chronic low-grade inflammation and neuronal deregulation are two components of a smoldering disease activity that drives the progression of disability in people with multiple sclerosis (MS). Although several therapies exist to dampen the acute inflammation that drives MS relapses, therapeutic options to halt chronic disability progression are a major unmet clinical need. The development of… Read more »

„A second birthday“? Experiences of persons with multiple sclerosis treated with autologous hematopoietic stem cell transplantation-a qualitative interview study.

Veröffentlicht: von & gespeichert unter Allgemein.

Introduction and objective: Autologous hematopoietic stem cell transplantation (aHSCT) is a promising treatment option for persons with multiple sclerosis (pwMS). Patients undergoing aHSCT face unique challenges in all aspects of life. In this study, we explored the lived experiences of pwMS undergoing aHSCT. Methods: Semi-structured interviews of 12 pwMS treated with aHSCT were conducted using… Read more »

Sex- and species-specific contribution of CD99 to T cell costimulation during multiple sclerosis.

Veröffentlicht: von & gespeichert unter Allgemein.

Background: Differences in immune responses between women and men are leading to a strong sex bias in the incidence of autoimmune diseases that predominantly affect women, such as multiple sclerosis (MS). MS manifests in more than twice as many women, making sex one of the most important risk factor. However, it is incompletely understood which… Read more »

Nurse-led immunotreatment DEcision Coaching In people with Multiple Sclerosis (DECIMS) – A cluster- randomised controlled trial and mixed methods process evaluation.

Veröffentlicht: von & gespeichert unter Allgemein.

Objective: To evaluate a nurse-led decision coaching programme aiming to redistribute health professionals‘ tasks to support immunotherapy decision-making in people with multiple sclerosis (MS). Methods: Cluster-randomised controlled trial with an accompanying mixed methods process evaluation (2014 – 2018). We planned to recruit 300 people with clinically isolated syndrome or relapsing-remitting MS facing immunotherapy decisions in… Read more »